This work is licensed under the Creative Commons Attribution 4.0 International License.
Ginsberg HN. Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006; 91:383–92.GinsbergHNReview: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia20069138392Search in Google Scholar
Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370:1829–39.Prospective Studies CollaborationLewingtonSWhitlockGClarkeRSherlikerPEmbersonJBlood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths2007370182939Search in Google Scholar
Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302:1993–2000.Emerging Risk Factors CollaborationDi AngelantonioESarwarNPerryPKaptogeSRayKKMajor lipids, apolipoproteins, and risk of vascular disease200930219932000Search in Google Scholar
Barter PJ. High-versus low-dose statin: effects on cardiovascular events and all-cause death. Circulation. 2018; 137:2013–5.BarterPJHigh-versus low-dose statin: effects on cardiovascular events and all-cause death201813720135Search in Google Scholar
Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002; 20:303–28.OlssonAGMcTaggartFRazaARosuvastatin: a highly effective new HMG-CoA reductase inhibitor20022030328Search in Google Scholar
Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017; 24:19–25.NaitoRMiyauchiKDaidaHRacial differences in the cholesterol-lowering effect of statin2017241925Search in Google Scholar
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018; 169:467–73.TriccoACLillieEZarinWO’BrienKKColquhounHLevacDPRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation201816946773Search in Google Scholar
Whirl-Carrillo M, McDonagh EM, Hebert JM, Sangkuhl GK, Thorn CF, Altman RB, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92:414–7.Whirl-CarrilloMMcDonaghEMHebertJMSangkuhlGKThornCFAltmanRBPharmacogenomics knowledge for personalized medicine2012924147Search in Google Scholar
Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008; 9:19–33.PasanenMKNeuvonenPJNiemiMGlobal analysis of genetic variation in SLCO1B1200891933Search in Google Scholar
Kaewboonlert N, Thitisopee W, Sirintronsopon W, Porntadavity S, Jeenduang N. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. J Clin Pharm Ther. 2018; 43:647–55.KaewboonlertNThitisopeeWSirintronsoponWPorntadavitySJeenduangNLack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients20184364755Search in Google Scholar
Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013; 14:1283–94.LeeHKHuMLuiSHoCSWongCKTomlinsonBEffects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients201314128394Search in Google Scholar
Hu M, Mak VWL, Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics. 2012; 22:803–6.HuMMakVWLTomlinsonBIntronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia2012228036Search in Google Scholar
Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015; 71:329–40.BirminghamBKBujacSRElsbyRAzumayaCTZalikowskiJChenYRosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States20157132940Search in Google Scholar
Kadam P, Ashavaid TF, Ponde CK, Rajani RM. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016; 41:329–33.KadamPAshavaidTFPondeCKRajaniRMGenetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population20164132933Search in Google Scholar
Donnelly LA, Doney ASF, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011; 89:210–6.DonnellyLADoneyASFTavendaleRLangCCPearsonERColhounHMCommon nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study2011892106Search in Google Scholar
Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006; 6:360–74.MangraviteLMThornCFKraussRMClinical implications of pharmacogenomics of statin treatment2006636074Search in Google Scholar
Liu N, Yang G, Hu M, Cai Y, Hu Z, Jia C, et al. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics. 2018; 19:1125–32.LiuNYangGHuMCaiYHuZJiaCAssociation of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin201819112532Search in Google Scholar
Renjie Z. The influence of gene mutation to statin responsiveness on high-risk CVD population in Chinese. Heart. 2012; 98(Suppl 2): E50. doi: 10.1136/heartjnl-2012-302920a.122RenjieZThe influence of gene mutation to statin responsiveness on high-risk CVD population in Chinese201298Suppl 2E5010.1136/heartjnl-2012-302920a.122Open DOISearch in Google Scholar
Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 2001; 42:1513–20.SchmitzGLangmannTHeimerlSRole of ABCG1 and other ABCG family members in lipid metabolism200142151320Search in Google Scholar
Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics. 2010; 20:634–7.HuMLuiSSMakVWChuTTLeeVWPoonEWPharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients2010206347Search in Google Scholar
Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010; 87:558–62.TomlinsonBHuMLeeVWLuiSSChuTTPoonEWABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin20108755862Search in Google Scholar
Jiang XY, Zhang Q, Chen P, Li SY, Zhang NN, Chen XD, et al. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther. 2012; 37:719–23.JiangXYZhangQChenPLiSYZhangNNChenXDCYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin20123771923Search in Google Scholar
Wei KK, Zhang LR, Zhang Y, Hu XJ. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. J Clin Pharm Ther. 2011; 36:725–33.WeiKKZhangLRZhangYHuXJInteractions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin20113672533Search in Google Scholar
Chien KL, Wang KC, Chen YC, Chao CL, Hsu HC, Chen MF, et al. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010; 11:309–17.ChienKLWangKCChenYCChaoCLHsuHCChenMFCommon sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins20101130917Search in Google Scholar
Srivastava A, Garg N, Srivastava A, Srivastava K, Mittal B. Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy. Dis Markers. 2010; 28:307–13.SrivastavaAGargNSrivastavaASrivastavaKMittalBEffect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy20102830713Search in Google Scholar
Li J, Wang LF, Li ZQ, Pan W. Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2009; 36:567–70.LiJWangLFLiZQPanWEffect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease20093656770Search in Google Scholar
Maxwell WD, Ramsey LB, Johnson SG, Moore KG, Shtutman M, Schoonover JH, et al. Impact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia. Pharmacotherapy. 2017; 37:1172–90.MaxwellWDRamseyLBJohnsonSGMooreKGShtutmanMSchoonoverJHImpact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia201737117290Search in Google Scholar
Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes. Am J Cardiovasc Drugs. 2004; 4:247–55.VermesAVermesIGenetic polymorphisms in cytochrome P450 enzymes2004424755Search in Google Scholar
Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017; 102:688–700.ZhouYIngelman-SundbergMLauschkeVMWorldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects2017102688700Search in Google Scholar
Hu M, Mak VW, Xiao Y, Tomlinson B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics. 2013; 14:25–34.HuMMakVWXiaoYTomlinsonBAssociations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia2013142534Search in Google Scholar
Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol. 2008; 64:877–82.GaoYZhangLRFuQCYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin20086487782Search in Google Scholar
Peng C, Ding Y, Yi X, Shen Y, Dong Z, Cao L, et al. Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population. Clin Ther. 2018; 40:469–77.e2.PengCDingYYiXShenYDongZCaoLPolymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population20184046977.e2Search in Google Scholar
Lin J, Zhang Y, Zhou H, Wang X, Wang W. CYP2C9 genetic polymorphism is a potential predictive marker for the efficacy of rosuvastatin therapy. Clin Lab. 2015; 61:1317–24.LinJZhangYZhouHWangXWangWCYP2C9 genetic polymorphism is a potential predictive marker for the efficacy of rosuvastatin therapy201561131724Search in Google Scholar
Finkelman RD, Wang TD, Wang Y, Azumaya CT, Birmingham BK, Wissmar J, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. Clin Pharmacol Drug Dev. 2015; 4:33–40.FinkelmanRDWangTDWangYAzumayaCTBirminghamBKWissmarJEffect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects201543340Search in Google Scholar
Li J, Wang X, Zhang Z, Zou J, Chen Y, Wang X, et al. Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia. Curr Med Res Opin. 2014; 30:223–8.LiJWangXZhangZZouJChenYWangXStatin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia2014302238Search in Google Scholar
Wei KK, Zhang LR. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin. Clin Drug Investig. 2015; 35:583–91.WeiKKZhangLRInteractions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin20153558391Search in Google Scholar
Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol. 2011; 51:181–8.LiYPZhangLRJiaMHuXJCYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women2011511818Search in Google Scholar
Pandey AV, Sproll P. Pharmacogenomics of human P450 oxidoreductase. Front Pharmacol. 2014; 5:103. doi: 10.3389/fphar.2014.00103PandeyAVSprollPPharmacogenomics of human P450 oxidoreductase2014510310.3389/fphar.2014.00103Open DOISearch in Google Scholar
Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984; 25:1277–94.MahleyRWInnerarityTLRallSCJrWeisgraberKHPlasma lipoproteins: apolipoprotein structure and function198425127794Search in Google Scholar
Wong K, Ryan RO. Characterization of apolipoprotein AV structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol. 2007; 18:319–24.WongKRyanROCharacterization of apolipoprotein AV structure and mode of plasma triacylglycerol regulation20071831924Search in Google Scholar
Baum L, Tomlinson B, Thomas GN. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet. 2003; 63:377–9.BaumLTomlinsonBThomasGNAPOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men2003633779Search in Google Scholar
Hubacek JA, Lánská V, Škodová Z, Adámková V, Poledne R. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur J Hum Genet. 2008; 16:135–8.HubacekJALánskáVŠkodováZAdámkováVPoledneRSex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels2008161358Search in Google Scholar
Son KY, Son H-Y, Chae J, Hwang J, Jang S, Yun JM, et al. Genetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men. Lipids Health Dis. 2015; 14:1–9.SonKYSonH-YChaeJHwangJJangSYunJMGenetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men20151419Search in Google Scholar
Hua S, Ma C, Zhang J, Li J, Wu W, Xu N, et al. Influence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects. Front Pharmacol. 2018; 9:352. doi: 10.3389/fphar.2018.00352HuaSMaCZhangJLiJWuWXuNInfluence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects2018935210.3389/fphar.2018.00352Open DOISearch in Google Scholar
Hu M, Mak VWL, Tomlinson B. Polymorphisms in apolipoprotein E and apolipoprotein AV do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia. J Clin Lipidol. 2012; 6:585–92.HuMMakVWLTomlinsonBPolymorphisms in apolipoprotein E and apolipoprotein AV do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia2012658592Search in Google Scholar
Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009; 50:S183–8.MahleyRWWeisgraberKHHuangYApolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS200950S1838Search in Google Scholar
Wanmasae S, Sirintronsopon W, Porntadavity S, Jeenduang N. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Cardiovasc Ther. 2017; 35:e12302. doi: 10.1111/1755-5922.12302WanmasaeSSirintronsoponWPorntadavitySJeenduangNThe effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients201735e1230210.1111/1755-5922.12302Open DOISearch in Google Scholar
Liu TN, Wu CT, He F, Yuan W, Li SX, Li HW, et al. Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia. Genet Mol Res. 2016; 15:1–6.LiuTNWuCTHeFYuanWLiSXLiHWRelationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia20161516Search in Google Scholar
Medina MW, Krauss RM. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med. 2009; 19:173–7.MedinaMWKraussRMThe role of HMGCR alternative splicing in statin efficacy2009191737Search in Google Scholar
Chung JY, Cho SK, Oh ES, Lee DH, Lim LA, Jang SB, et al. Effect of HMGCR variant alleles on low-density lipoprotein cholesterol – lowering response to atorvastatin in healthy Korean Subjects. J Clin Pharmacol. 2012; 52:339–46.ChungJYChoSKOhESLeeDHLimLAJangSBEffect of HMGCR variant alleles on low-density lipoprotein cholesterol – lowering response to atorvastatin in healthy Korean Subjects20125233946Search in Google Scholar
Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009; 284:28856–64.PoirierSMayerGPouponVMcPhersonPSDesjardinsRLyKDissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route20092842885664Search in Google Scholar
Hubacek JA, Bobkova D. Role of cholesterol 7α-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther. 2006; 10:93–100.HubacekJABobkovaDRole of cholesterol 7α-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering20061093100Search in Google Scholar
Liu N, Yang G, Liu Y, Hu M, Cai Y, Hu Z, et al. Effect of cytochrome P450 7A1 (CYP7A1) polymorphism on lipid responses to simvastatin treatment. J Cardiovasc Pharmacol. 2020; 75:168–73.LiuNYangGLiuYHuMCaiYHuZEffect of cytochrome P450 7A1 (CYP7A1) polymorphism on lipid responses to simvastatin treatment20207516873Search in Google Scholar
Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet. 1989; 35:49–56.KondoIBergKDraynaDLawnRDNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels1989354956Search in Google Scholar
Kuivenhoven JA, de Knijff P, Boer JMA, Smalheer HA, Botma G-J, Seidell JC, et al. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1997; 17:560–8.KuivenhovenJAde KnijffPBoerJMASmalheerHABotmaG-JSeidellJCHeterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels1997175608Search in Google Scholar
Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis. 2002; 161:469–74.LiuSSchmitzCStampferMJSacksFHennekensCHLindpaintnerKA prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men200216146974Search in Google Scholar
Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med. 2002; 80:753–69.MeadJRIrvineSARamjiDPLipoprotein lipase: structure, function, regulation, and role in disease20028075369Search in Google Scholar
Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000; 1529:245–56.JonasALecithin cholesterol acyltransferase2000152924556Search in Google Scholar
Schugar RC, Brown JM. Emerging roles of Flavin Monooxygenase 3 (FMO3) in cholesterol metabolism and atherosclerosis. Curr Opin Lipidol. 2015; 26:426–31.SchugarRCBrownJMEmerging roles of Flavin Monooxygenase 3 (FMO3) in cholesterol metabolism and atherosclerosis20152642631Search in Google Scholar
VanPatten S, Ranginani N, Shefer S, Nguyen LB, Rossetti L, Cohen DE. Impaired biliary lipid secretion in obese Zucker rats: leptin promotes hepatic cholesterol clearance. Am J Physiol Gastrointest Liver Physiol. 2001; 281:G393–404.VanPattenSRanginaniNSheferSNguyenLBRossettiLCohenDEImpaired biliary lipid secretion in obese Zucker rats: leptin promotes hepatic cholesterol clearance2001281G393404Search in Google Scholar
Li K, Liu Y, Venners SA, Hsu YH, Jiang S, Weinstock J, et al. Effects of LEP G2548A and LEPR Q223R polymorphisms on serum lipids and response to simvastatin treatment in Chinese patients with primary hyperlipidemia. Clin Appl Thromb Hemost. 2017; 23:336–44.LiKLiuYVennersSAHsuYHJiangSWeinstockJEffects of LEP G2548A and LEPR Q223R polymorphisms on serum lipids and response to simvastatin treatment in Chinese patients with primary hyperlipidemia20172333644Search in Google Scholar
Sun Y-M, Wang L-F, Li J, Li Z-Q, Pan W. The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease. Eur J Clin Pharmacol. 2009; 65:157–61.SunY-MWangL-FLiJLiZ-QPanWThe 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease20096515761Search in Google Scholar
Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018; 14:137–43.ShunmoogamNNaidooPChiltonRParaoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance20181413743Search in Google Scholar
Fu R, Sun Y-M, Su Y, Wu Y, Luan Y. Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2008; 35:982–3.FuRSunY-MSuYWuYLuanYEffect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease2008359823Search in Google Scholar
Meyer Zu Schwabedissen HE, Böttcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology. 2010; 52:1797–807.Meyer Zu SchwabedissenHEBöttcherKChaudhryAKroemerHKSchuetzEGKimRBLiver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B12010521797807Search in Google Scholar
Hu M, Lui SSH, Tam L-S, Li EK, Tomlinson B. The farnesoid X receptor-1G>T polymorphism influences the lipid response to rosuvastatin. J Lipid Res. 2012; 53:1384–9.HuMLuiSSHTamL-SLiEKTomlinsonBThe farnesoid X receptor-1G>T polymorphism influences the lipid response to rosuvastatin20125313849Search in Google Scholar
Rafeeq MM, Ahmad F, Rahman SZ, Siddiqi SS, Shakil S. Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome. Pharmacogenomics. 2016; 17:2015–24.RafeeqMMAhmadFRahmanSZSiddiqiSSShakilSEffect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome201617201524Search in Google Scholar
Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010; 235:172–89.FreemanGJCasasnovasJMUmetsuDTDeKruyffRHTIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity201023517289Search in Google Scholar
Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Biosci Rep. 2018; 38:BSR20171058. doi: 10.1042/BSR20171058ZhangQHYinRXChenWXCaoXLChenYMAssociation between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy201838BSR2017105810.1042/BSR20171058Open DOISearch in Google Scholar
Takahashi T, Takahashi K, Yamashina M, Maesawa C, Kajiwara T, Taneichi H, et al. Association of the TNF-α-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects. Diabetes Care. 2010; 33:463–6.TakahashiTTakahashiKYamashinaMMaesawaCKajiwaraTTaneichiHAssociation of the TNF-α-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects2010334636Search in Google Scholar
Xu Y, Wang Y, Zhi J, Qi L, Zhang T, Li X. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. BMC Pharmacol Toxicol. 2017; 18:1–6.XuYWangYZhiJQiLZhangTLiXImpact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease20171816Search in Google Scholar
Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; 40:189–97.KathiresanSMelanderOGuiducciCSurtiABurttNPRiederMJSix new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans20084018997Search in Google Scholar
Tai ES, Sim XL, Ong TH, Wong TY, Saw SM, Aung T, et al. Polymorphisms at newly identified lipid-associated loci are Pharmacogenomics of statin in Asians associated with blood lipids and cardiovascular disease in an Asian Malay population. J Lipid Res. 2009; 50:514–20.TaiESSimXLOngTHWongTYSawSMAungTPolymorphisms at newly identified lipid-associated loci are Pharmacogenomics of statin in Asians associated with blood lipids and cardiovascular disease in an Asian Malay population20095051420Search in Google Scholar
Yan TT, Yin RX, Li Q, Huang P, Zeng XN, Huang KK, et al. Sex-specific association of rs16996148 SNP in the NCAN/CILP2/PBX4 and serum lipid levels in the Mulao and Han populations. Lipids Health Dis. 2011; 10:1–15.YanTTYinRXLiQHuangPZengXNHuangKKSex-specific association of rs16996148 SNP in the NCAN/CILP2/PBX4 and serum lipid levels in the Mulao and Han populations201110115Search in Google Scholar
Paradis ME, Lamarche B. Endothelial lipase: its role in cardiovascular disease. Can J Cardiol. 2006; 22:31B–4B.ParadisMELamarcheBEndothelial lipase: its role in cardiovascular disease20062231B4BSearch in Google Scholar
Cai G, Zhang B, Shi G, Weng W, Yang L, Xue S. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin. Lipids Health Dis. 2016; 15:1–6.CaiGZhangBShiGWengWYangLXueSEndothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin20161516Search in Google Scholar
Jiang S, Venners SA, Li K, Hsu Y-H, Weinstock J, Zou Y, et al. Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation. Oncotarget. 2017; 8:107565–76.JiangSVennersSALiKHsuY-HWeinstockJZouYEffect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation2017810756576Search in Google Scholar
Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, et al. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet. 2016; 31:467–70.SaiKKajinamiKAkaoHIwadareMSato-IshidaRKawaiYA possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients20163146770Search in Google Scholar
Liu J-E, Liu X-Y, Chen S, Zhang Y, Cai L-Y, Yang M, et al. SLCO1B1 521T>C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study. Eur J Clin Pharmacol. 2017; 73:1409–16.LiuJ-ELiuX-YChenSZhangYCaiL-YYangMSLCO1B1 521T>C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study201773140916Search in Google Scholar
Zhong Z, Wu H, Li B, Li C, Liu Z, Yang M, et al. Analysis of SLCO 1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. J Clin Lab Anal. 2018; 32:e22408. doi: 10.1002/jcla.22408ZhongZWuHLiBLiCLiuZYangMAnalysis of SLCO 1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China201832e2240810.1002/jcla.22408Open DOISearch in Google Scholar
Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl-coenzyme A reductase–associated autoimmune myopathy. Arthritis Care Res. 2012; 64:1233–7.MammenALGaudetDBrissonDChristopher-StineLLloydTELeffellMSIncreased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl-coenzyme A reductase–associated autoimmune myopathy20126412337Search in Google Scholar
Suarez-Kurtz G. Ethnic differences in drug therapy: a pharmacogenomics perspective. Expert Rev Clin Pharmacol. 2008; 1:337–9.Suarez-KurtzGEthnic differences in drug therapy: a pharmacogenomics perspective200813379Search in Google Scholar
Ho WF, Koo SH, Yee JY, Lee EJD. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet. 2008; 23:476–82.HoWFKooSHYeeJYLeeEJDGenetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore20082347682Search in Google Scholar
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009; 54:1609–16.VooraDShahSHSpasojevicIAliSReedCRSalisburyBAThe SLCO1B1*5 genetic variant is associated with statin-induced side effects200954160916Search in Google Scholar
SEARCH Study Collaborative Group; Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007; 154:815–23, 823.e1–6.SEARCH Study Collaborative GroupBowmanLArmitageJBulbuliaRParishSCollinsRStudy of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors200715481523823.e16Search in Google Scholar
Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012; 92:112–7.WilkeRARamseyLBJohnsonSGMaxwellWDMcLeodHLVooraDThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy2012921127Search in Google Scholar
Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J. 2018; 70:S120–5.RamakumariNIndumathiBKatkamSKKutalaVKImpact of pharmacogenetics on statin-induced myopathy in South-Indian subjects201870S1205Search in Google Scholar
C. Thambiah S, Meor Anuar Shuhaili MFR, Chew BH, Samsudin IN, Abdul Rahman H, Stanslas J, et al. A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort. Biomarkers. 2019; 24:659–65.C. ThambiahSMeor Anuar ShuhailiMFRChewBHSamsudinINAbdul RahmanHStanslasJA pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort20192465965Search in Google Scholar
Food and Drug Administration. Crestor (rosuvastatin calicum) prescribing information. Washington (DC): FDA; 2015.Food and Drug AdministrationWashington (DC)FDA2015Search in Google Scholar
Wu H-F, Hristeva N, Chang J, Liang X, Li R, Frassetto L, et al. Rosuvastatin pharmacokinetics in Asian and white Subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions. J Pharma Sci. 2017; 106:2751–7.WuH-FHristevaNChangJLiangXLiRFrassettoLRosuvastatin pharmacokinetics in Asian and white Subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions201710627517Search in Google Scholar
Arrigoni E, Del Re M, Fidilio L, Fogli S, Danesi R, Di Paolo A. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017; 18:104. doi: 10.3390/ijms18010104ArrigoniEDel ReMFidilioLFogliSDanesiRDi PaoloAPharmacogenetic foundations of therapeutic efficacy and adverse events of statins20171810410.3390/ijms18010104Open DOISearch in Google Scholar